Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · HALEOSLABS

HALEOSLABS

HealthcarePharmaceuticals & Biotechnology₹498 cr market cap
₹1580.50 ▼ -3.18% today As of 19 Nov 2026
52-week low ₹1126.5052-week high ₹1690.10

-3.4% from the 52-week high · +44.9% above the low

SMS Lifesciences India Ltd. engages in manufacturing and selling of active pharmaceutical products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2017-08-17. The firm's products include Ranitidine HCL (Form-2) USP / Ph.Eur, Famotidine USP / Ph. Eur / JP, Itraconazole USP / Ph.Eur / JP, Lanoconazole USP / JP and Sildenafil Citrate USP / Ph.Eur. The firm's manufacturing facilities are located at Kazipally and Jeedimetla, Hyderabad. The firm's wholly owned subsidiary is Mahi Drugs Private limited.

The short version. HALEOSLABS reported revenue of ₹91 crore for Sep 2026, up 12.3% from a year earlier. Net profit was ₹3 crore (down 50.0% year on year). Return on equity was 8.1% in Mar 2026. Promoter holding was 72.11% in Sep 2026, up 0.70 points over 8 quarters.

1 · The price

How has the stock traded?

HALEOSLABS trades 3.4% below its 52-week high and 44.9% above its 52-week low.

Change over period: —

1M+6.1%
3M+12.1%
6M+1.5%
1Y—

2 · The business

Is it growing?

Sales, year on year+12.3%

Sep 2026 revenue of ₹91 cr.

Profit, year on year-50.0%

Sep 2026 net profit of ₹3 cr.

Net margin3.6%

3.9 pts lower than a year earlier.

3-year growth14.7% profit

Revenue compounded at 1.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue9173759581838985
Net profit33076435
Net margin %3.63.60.67.07.55.03.36.5
EPS (₹)10.778.751.4421.8920.1913.759.8318.08

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue334345306316350266261
Net profit1720911251410
Net margin %5.25.83.03.67.25.13.9
EPS (₹)57.2666.5130.0837.9283.6144.8433.68

3 · The quality

How well does it turn capital into profit?

Return on equity was 8.1% in Mar 2026; debt to equity is 0.51.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %8.110.25.16.8
Return on capital %10.614.18.18.9
EBITDA margin %14.014.311.310.7
Net margin %5.15.82.93.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR1.8%4.7%
Profit CAGR14.7%5.0%
Debt to equity0.51
Interest cover4.9x
Current ratio1.04
P/E ratio38.0

4 · The owners

Who holds it, and are they adding?

Promoter holding72.11%

Up 0.7 pts over 8 quarters.

Domestic institutions0.31%

Up 0.31 pts over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter71.4171.4171.4171.4171.872.1172.1172.11+0.7
FII000.03000000
DII0000.030.290.30.310.31+0.31
Public28.5928.5928.5628.5727.9127.627.5827.58-1.01

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for HALEOSLABS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about HALEOSLABS

What is the HALEOSLABS share price?

HALEOSLABS (HALEOSLABS) last closed at ₹1,580.50, down 3.18% on the day. Its 52-week range is ₹1,126.50 to ₹1,690.10.

What is the market cap of HALEOSLABS?

HALEOSLABS has a market capitalisation of about ₹498 crore. Its price-to-earnings ratio is 38.0.

How are HALEOSLABS's latest results?

HALEOSLABS reported revenue of ₹91 crore for Sep 2026, up 12.3% from a year earlier. Net profit was ₹3 crore (down 50.0% year on year). Return on equity was 8.1% in Mar 2026. Promoter holding was 72.11% in Sep 2026, up 0.70 points over 8 quarters.

Who owns HALEOSLABS?

As of Sep 2026, shareholding was: Promoter 72.11%, DII 0.31%, Public 27.58%.

How many mutual funds hold HALEOSLABS?

0 mutual fund schemes held HALEOSLABS in October 2026. That compares with 0 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 24 Sep 2025 · Dividend - Rs. 1.5
  • 23 Sep 2024 · Dividend - Rs. 1.5
  • 22 Sep 2023 · Dividend - Rs. 1.5
  • 22 Sep 2022 · Dividend - Rs. 1.5
  • 20 Sep 2021 · Dividend - Rs. 1.5
  • 19 Sep 2019 · Dividend - Rs. 1.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.